vTv Therapeutics Inc. Working Capital

Working Capital of VTVT for past 10 years: annual, quarterly and twelve month trailing (TTM) including Working Capital growth rates and interactive chart. Working capital, also known as net working capital (NWC), is the difference between a company’s current assets, such as cash, accounts receivable (customers’ unpaid bills) and inventories of raw materials and finished goods, and its current liabilities, such as accounts payable. Net operating working capital is a measure of a company's liquidity and refers to the difference between operating current assets and operating current liabilities. In many cases these calculations are the same and are derived from company cash plus accounts receivable plus inventories, less accounts payable and less accrued expenses. Working capital is a measure of a company's liquidity, operational efficiency and its short-term financial health. If a company has substantial positive working capital, then it should have the potential to invest and grow. If a company's current assets do not exceed its current liabilities, then it may have trouble growing or paying back creditors, or even go bankrupt.


Highlights and Quick Summary

  • Working Capital for the quarter ending September 29, 2020 was $-4.62 Million (a -0.39% decrease compared to previous quarter)
  • Year-over-year quarterly Working Capital decreased by -56.2%
  • Annual Working Capital for 2019 was $-10.5 Million (a -31.38% decrease from previous year)
  • Annual Working Capital for 2018 was $-15.4 Million (a 133.96% increase from previous year)
  • Annual Working Capital for 2017 was $-6.57 Million (a -116.14% decrease from previous year)
Visit stockrow.com/VTVT for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Working Capital of vTv Therapeutics Inc.

Most recent Working Capitalof VTVT including historical data for past 10 years.

Interactive Chart of Working Capital of vTv Therapeutics Inc.

vTv Therapeutics Inc. Working Capital for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 $-4.62 $-4.64 $-8.47
2019 $-10.54 $-10.9 $-13.38 $-11.1 $-10.54
2018 $-15.36 $-19.41 $-25.48 $-17.35 $-15.36
2017 $-6.57 $9.29 $21.9 $34.82 $-6.57
2016 $40.68 $41.53 $54.44 $68.38 $40.68
2015 $81.46 $91.73 $-60.3 $81.46
2014 $-5.25
2013 $-85.16 $-85.16

Business Profile of vTv Therapeutics Inc.

Sector: Healthcare
Industry: Biotechnology
vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops orally administered small molecule drug candidates to fill unmet medical needs. The company is developing Azeliragon, an orally administered, small molecule antagonist targeting the receptor for advanced glycation end products, which is in Phase II clinical trials for the treatment of mild Alzheimer's disease. It is also developing TTP399, an orally administered, liver-selective glucokinase activator that has completed Phase II clinical trials to treat type 2 diabetes, as well as is in Phase II/III clinical trials for treating type 1 diabetes; and TTP273, an orally administered, non-peptidic agonist that targets the glucagon-like peptide-1 receptor, which has completed Phase II clinical trials for the treatment of type 2 diabetes. In addition, the company is developing HPP737, HPP971, and HPP3033 for the treatment of chronic disease. It has a license agreement with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593. vTv Therapeutics Inc. also has license and research agreements with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; Novo Nordisk A/S; and Columbia University. The company was founded in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.